## Semi Kim

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1457869/publications.pdf

Version: 2024-02-01

		516561	642610
23	693	16	23
papers	citations	h-index	g-index
	22		001
23	23	23	801
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Therapeutic effects of TM4SF5-targeting chimeric and humanized monoclonal antibodies in hepatocellular and colon cancer models. Molecular Therapy - Oncolytics, 2022, 24, 452-466.	2.0	3
2	TM4SF5-mediated liver malignancy involves NK cell exhaustion-like phenotypes. Cellular and Molecular Life Sciences, 2022, 79, 1.	2.4	13
3	Differential <scp>TM4SF5</scp> â€mediated <scp>SIRT1</scp> modulation and metabolic signaling in nonalcoholic steatohepatitis progression. Journal of Pathology, 2021, 253, 55-67.	2.1	20
4	A New Surface Charge Neutralizing Nano-Adjuvant to Potentiate Polymyxins in Killing Mcr-1 Mediated Drug-Resistant Escherichia coli. Pharmaceutics, 2021, 13, 250.	2.0	15
5	TMEM52B suppression promotes cancer cell survival and invasion through modulating E-cadherin stability and EGFR activity. Journal of Experimental and Clinical Cancer Research, 2021, 40, 58.	3.5	8
6	Bovine Serum Albumin-Immobilized Black Phosphorus-Based $\hat{I}^3$ -Fe2O3 Nanocomposites: A Promising Biocompatible Nanoplatform. Biomedicines, 2021, 9, 858.	1.4	6
7	TMPRSS4 promotes cancer stem–like properties in prostate cancer cells through upregulation of SOX2 by SLUG and TWIST1. Journal of Experimental and Clinical Cancer Research, 2021, 40, 372.	<b>3.</b> 5	31
8	A New Nano-Platform of Erythromycin Combined with Ag Nano-Particle ZnO Nano-Structure against Methicillin-Resistant Staphylococcus aureus. Pharmaceutics, 2020, 12, 841.	2.0	21
9	A nontoxic biocompatible nanocomposite comprising black phosphorus with Au–γ-Fe <sub>2</sub> O <sub>3</sub> nanoparticles. RSC Advances, 2020, 10, 16162-16167.	1.7	9
10	Anti-cancer activity of the novel 2-hydroxydiarylamide derivatives IMD-0354 and KRT1853 through suppression of cancer cell invasion, proliferation, and survival mediated by TMPRSS4. Scientific Reports, 2019, 9, 10003.	1.6	22
11	Transmembrane 4ÂL Six Family Member 5 Senses Arginine for mTORC1 Signaling. Cell Metabolism, 2019, 29, 1306-1319.e7.	7.2	50
12	Preparation of siRNA encapsulated nanoliposomes suitable for siRNA delivery by simply discontinuous mixing. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1318-1325.	1.4	16
13	Cooperation between ZEB2 and Sp1 promotes cancer cell survival and angiogenesis during metastasis through induction of survivin and VEGF. Oncotarget, 2018, 9, 726-742.	0.8	16
14	Anti-cancer Activity of Novel TM4SF5-Targeting Antibodies through TM4SF5 Neutralization and Immune Cell-Mediated Cytotoxicity. Theranostics, 2017, 7, 594-613.	4.6	19
15	TMPRSS4 induces invasion and proliferation of prostate cancer cells through induction of Slug and cyclin D1. Oncotarget, 2016, 7, 50315-50332.	0.8	31
16	Twist1 and AP-1 cooperatively upregulate integrin $\hat{l}\pm 5$ expression to induce invasion and the epithelial $\hat{a}\in$ "mesenchymal transition. Carcinogenesis, 2015, 36, 327-337.	1.3	47
17	TMPRSS4 induces cancer cell invasion through pro-uPA processing. Biochemical and Biophysical Research Communications, 2014, 446, 1-7.	1.0	29
18	TMPRSS4 upregulates uPA gene expression through JNK signaling activation to induce cancer cell invasion. Cellular Signalling, 2014, 26, 398-408.	1.7	32

## Ѕемі Кім

#	Article	IF	CITATIONS
19	Membrane Proteins Involved in Epithelial-Mesenchymal Transition and Tumor Invasion: Studies on TMPRSS4 and TM4SF5. Genomics and Informatics, 2014, 12, 12.	0.4	25
20	TMPRSS4 induces invasion and epithelial-mesenchymal transition through upregulation of integrin $\hat{A}5$ and its signaling pathways. Carcinogenesis, 2010, 31, 597-606.	1.3	96
21	The extracellular loop 2 of TM4SF5 inhibits integrin $\hat{l}\pm2$ on hepatocytes under collagen type I environment. Carcinogenesis, 2009, 30, 1872-1879.	1.3	25
22	Cooperation between integrin $\hat{l}\pm 5$ and tetraspan TM4SF5 regulates VEGF-mediated angiogenic activity. Blood, 2009, 113, 1845-1855.	0.6	56
23	Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. Journal of Clinical Investigation, 2008, 118, 1354-1366.	3.9	103